C-methionine PET in assessment of brain lesions in patients with glial tumors after combined treatment

Skvortsova, T. Yu.; Гурчин, А. Ф.; Savintseva, Zh. I.

doi:10.17116/neiro20198302127

Cited by 2 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 1 ( 9 - 12 , 16 , 26 - 40 ) demonstrates the characteristics of the included studies. Among the 20 included studies, 3 studies ( 11 , 12 , 31 ) had a prospective design. All studies used the RANO criteria as the gold standard to identify glioma PsP, with 14 studies ( 9 - 12 , 26 , 28 , 30 - 37 ) using pathology and MRI follow-up, 2 studies ( 27 , 29 ) using pathology as the sole reference standard, and 4 studies ( 16 , 38 - 40 ) using MRI follow-up alone.…”

Section: Resultsmentioning

confidence: 99%

“…All studies used the RANO criteria as the gold standard to identify glioma PsP, with 14 studies ( 9 - 12 , 26 , 28 , 30 - 37 ) using pathology and MRI follow-up, 2 studies ( 27 , 29 ) using pathology as the sole reference standard, and 4 studies ( 16 , 38 - 40 ) using MRI follow-up alone. The most commonly evaluated radiotracer was 18 F-FET; in addition, 3 studies tested 11 C-MET ( 11 , 29 , 32 ), 2 tested 18 F-FDOPA ( 12 , 16 ), and 1 tested 18 F-FDG ( 9 ). Each study reported the treatment schemes of patients with glioma to different degrees.…”

Section: Resultsmentioning

confidence: 99%

“…Before pooling diagnostic values, we screened the PET parameters of each study according to the principle of data extraction. Among all included studies, the most effective parameter was the maximum tumor-to-brain ratio (TBRmax) in 10 studies ( 10 , 11 , 16 , 28 , 30 , 31 , 33 , 36 , 38 , 39 ), the mean tumor-to-brain ratio (TBRmean) in 3 studies ( 34 , 37 , 40 ), and the relative change of TBR in 2 studies ( 27 , 29 ). In the 5 remaining studies ( 9 , 12 , 26 , 32 , 35 ), the most effective parameter was the metabolic tumor volume (MTV), slope, standardized uptake values of the lesion divided by standardized uptake values of the normal (nSUVmax), radiomics signature, and combined parameter ( Table 1 ), respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Finally, the meta-regression showed that the summary sensitivity and specificity of non- 18 F-FET PET were significantly higher than those of 18 F-FET PET (sensitivity: 0.93 vs. 0.80, P<0.001; specificity: 0.91 vs. 0.81, P<0.001). However, there were only six eligible studies with non- 18 F-FET radiotracer including one 18 F-FDG study ( 9 ), three 11 C-MET studies ( 11 , 29 , 32 ) and two 18 F-FDOPA studies ( 12 , 16 ). Obviously, the present evidence is insufficiently robust to prove that the summary accuracy of imaging using other radiotracers for identification of glioma PsP is superior to that of 18 F-FET imaging.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis

Ouyang¹,

Zheng²,

Duan³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background Positron emission tomography (PET) imaging is a promising molecular neuroimaging technique and has been proposed as one of the criteria for glioma management. However, there is some controversy concerning the diagnostic accuracy of PET using different radiotracers to differentiate between glioma pseudoprogression (PsP) and true progression (TPR). The purpose of this meta-analysis was to systematically evaluate the methodological quality and clinical value of original studies for distinguishing PsP from TPR in glioma. Methods The Medline, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception until September 1, 2022. Retrieved clinical studies only investigated the PsP cases but did not include the cases of radiation necrosis or other treatment-related changes. Eligible studies were screened for data extraction and evaluated by 2 independent reviewers using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. A random effects model was used to describe summary receiver operating characteristics. Meta-regression and subgroup analyses were applied to identify any sources of heterogeneity. Results The meta-analysis included 20 studies, comprising 317 (30.9%) patients with PsP and 708 (69.1%) with TPR. The summary sensitivity and specificity of general PET for identifying PsP were 0.86 [95% confidence interval (CI): 0.77–0.91] and 0.84 (95% CI: 0.79–0.88), respectively. The statistical heterogeneity was explained by sample size, study design, World Health Organization (WHO) grade, gold standard, and radiotracer type. The summary sensitivity and specificity of O-(2- 18 F-fluoroethyl)-L-tyrosine ( 18 F-FET PET) were 0.80 (95% CI: 0.68–0.88) and 0.81 (95% CI: 0.75–0.85), respectively. The maximum tumor-to-brain ratio (TBRmax) and the mean tumor-to-brain ratio (TBRmean) both showed excellent diagnostic performance in 18 F-FET studies, the summary sensitivity was 0.83 (95% CI: 0.72–0.91) and 0.79 (95% CI: 0.65–0.98), respectively, and the specificity was 0.76 (95% CI: 0.68–0.84) and 0.78 (95% CI: 0.64–0.88), respectively. Conclusions PET imaging is generally accurate in identifying glioma PsP. Considering the credibility of meta-evidence and the practicability of using radiotracer, 18 F-FET PET holds the highest clinical value, while TBRmax and TBRmean should be regarded as reliable parameters. PET used with the radiotracers and multiple-parameter combinations of PET with magnetic resonance imaging (MRI) and radiomics analysis have broad research and application prospects, whose diagnostic values for identifying glioma PsP warrant further investigation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis

Ouyang¹,

Zheng²,

Duan³

et al. 2023

Quant Imaging Med Surg

View full text Add to dashboard Cite

show abstract

“…Было установлено, что высокий уровень захвата 11 С-МЕТ в первичной опухоли головного мозга до начала лечения свидетельствует о неблагоприятном прогнозе. Также следует отметить, что снижение уровня захвата 11 С-МЕТ в процессе консервативной терапии достоверно отражает эффективность проводимого лечения [56][57][58].…”

Section: резюмеunclassified

Modern methods for radionuclide diagnosis of tumors and non-tumor pathologies of the brain

et al. 2022

View full text Add to dashboard Cite

The review analyzes the global experience in the application of nuclear medicine techniques for diagnosis of tumors and non-tumor pathologies of the brain. The main groups of radiopharmaceuticals currently used for imaging of malignant brain tumors and diagnosis of cognitive impairments and neurotransmitter system disturbances by means of single-photon emission computed tomography and positron emission tomography are described.Modern approaches to the application of methods for radionuclide diagnosis in neuro-oncology and neurology are compared, and the main trends in production of new, more specific radiopharmaceuticals for visualizing brain tumors of various degrees of malignancy and diagnosing non-tumor pathologies of the brain are described. The review discusses the advantages and disadvantages of currently used techniques and radiopharmaceuticals for imaging of central nervous system disorders, depending on the clinical situation and specific diagnostic tasks.In addition, the review presents consolidated recommendations of the leading scientific schools in neuro-oncology on the use of nuclear medicine techniques in patients with brain tumors at the stages of treatment and follow-up. The presented article examines the experience of domestic scientific schools in the development of radiopharmaceuticals for neuro-oncology. The features of the development and use of new radiopharmaceuticals in patients with brain tumors and neurodegenerative diseases are highlighted. The review is based on the analysis of literature included in the Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, and RSCI databases.

show abstract

C-methionine PET in assessment of brain lesions in patients with glial tumors after combined treatment

Cited by 2 publications

References 9 publications

Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis

Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis

Modern methods for radionuclide diagnosis of tumors and non-tumor pathologies of the brain

Contact Info

Product

Resources

About